Amylyx Pharmaceuticals, Inc.

AMLX

US03237H1014

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.76 ^USD	-1.12%		-5.88%	-88.04%

Apr. 11	Baird Trims Amylyx Pharmaceuticals' Price Target to $3 From $4, Maintains Neutral Rating	MT
Apr. 10	Transcript : Amylyx Pharmaceuticals, Inc. - Special Call

Amylyx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022

November 10, 2022 at 04:01 pm EST

Amylyx Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported revenue was USD 0.345 million compared to USD 0.285 million a year ago. Net loss was USD 53.76 million compared to USD 23.14 million a year ago. Basic loss per share from continuing operations was USD 0.92 compared to USD 3.42 a year ago.
For the nine months, revenue was USD 0.345 million compared to USD 0.285 million a year ago. Net loss was USD 155.67 million compared to USD 59.59 million a year ago. Basic loss per share from continuing operations was USD 2.77 compared to USD 9.2 a year ago.

Latest news about Amylyx Pharmaceuticals, Inc.

Baird Trims Amylyx Pharmaceuticals' Price Target to $3 From $4, Maintains Neutral Rating	Apr. 11	MT
Transcript : Amylyx Pharmaceuticals, Inc. - Special Call	Apr. 10
Amylyx Pharmaceuticals Announces Interim Data from Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome	Apr. 10	CI
Deutsche Bank Cuts Amylyx Pharmaceuticals' Price Target to $4 From $8, Maintains Buy Rating	Apr. 05	MT
Sector Update: Health Care Stocks Mixed in Afternoon Trading	Apr. 04	MT
Top Midday Stories: Ford Delays Start of EV Production at Canadian Plant; Alphabet Mulls Acquiring HubSpot; Boeing Paid Alaska Airlines $160 Million in Q1 for Fleet Grounding; Taiwan Semiconductor Expects Full Recovery of Top Plant on Thursday; Coinbase Registered as Restricted Dealer in Canada; CSX Completes First Shipments Using New Rail Post Baltimore Bridge Collapse; Levi Shares Soar on Earnings Beat; Amylyx to Discontinue Marketing Authorizations for Relyvrio	Apr. 04	MT
Amylyx Pharmaceuticals Pulling ALS Drug, Cutting Staff by 70%	Apr. 04	DJ
Amylyx Pharmaceuticals to Discontinue Relyvrio/Albrioza in US, Canada; Slashes Workforce by 70%	Apr. 04	MT
Amylyx Pharmaceuticals, Inc. Announces Formal Intention to Remove Relyvrio/Albriza from the Market	Apr. 04	CI
Sector Update: Health Care Stocks Edge Up Late Monday Afternoon	Mar. 18	MT
Top Midday Decliners	Mar. 18	MT
Mizuho Downgrades Amylyx Pharmaceuticals to Neutral From Buy After Negative Results From Phase 3 PHEONIX Study, Adjusts PT to $4 From $32	Mar. 18	MT
Amylyx Pharmaceuticals, Inc. Appoints Bernhardt Zeiher to Its Board of Directors	Mar. 14	CI
H.C. Wainwright Adjusts Price Target on Amylyx Pharmaceuticals to $8 From $42, Maintains Buy Rating	Mar. 12	MT
North American Morning Briefing : Inflation Data -2-	Mar. 12	DJ
Deutsche Bank Cuts Amylyx Pharmaceuticals' Price Target to $8 From $36, Maintains Buy Rating	Mar. 11	MT
Goldman Sachs Downgrades Amylyx Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $4 From $40	Mar. 11	MT
Leerink Partners Downgrades Amylyx Pharmaceuticals to Market Perform From Outperform	Mar. 11	MT
Baird Downgrades Amylyx Pharmaceuticals to Neutral From Outperform, Cuts Price Target to $4 From $37	Mar. 11	MT
North American Morning Briefing : Stock Futures -2-	Mar. 11	DJ
Health Care Flat After Trial Setbacks -- Health Care Roundup	Mar. 08	DJ
Sector Update: Health Care Stocks Ease Late Afternoon	Mar. 08	MT
Top Midday Decliners	Mar. 08	MT
Sector Update: Health Care Stocks Lower Friday Afternoon	Mar. 08	MT
News Highlights : Top Company News of the Day - Friday at 1 PM ET	Mar. 08	DJ

Chart Amylyx Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate, AMX0035 (sodium phenylbutyrate and taurursodiol, also known as ursodoxicoltaurine) for the treatment of amyotrophic lateral sclerosis (ALS). RELYVRIO (also known as AMX0035), an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol is approved to treat ALS in adults in the United States. AMX0035 is a dual unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). Its development of antisense oligonucleotides (ASOs), including lead ASO AMX0114, which targets calpain-2 (CAPN2), a gene encoding calcium-dependent proteolytic enzyme which has been implicated in the pathogenesis of ALS and other neurodegenerative diseases.

Sector

Pharmaceuticals

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Amylyx Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1.76 USD

Average target price

4.25 USD

Spread / Average Target

+141.48%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
AMYLYX PHARMACEUTICALS, INC.	-88.04%	120M
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B
INNOVENT BIOLOGICS, INC.	-8.42%	8.12B

Biopharmaceuticals